The preliminary data with lung cancer with zybrestat was positive!
Wow, East! Almost pumping! Did not recognize you! ;-) But we are in agreement! Oxigene must have a partner to run phase III in NCSLC and Ovarian. But that has been the case from the beginning. I have a slide from 2003 with the long term goals.
As I see it we have some different partnering options:
Ophthalmology! Oxigene has stated several times that this is subject to out licensing! CA4P Oncology! Oxigene stated in the last cc that they are conducting discussion with several parties in different stages. Oxi4503, Not been mentioned in partnering. I think Oxigene will try to keep this in house if they can! All indications deal, not been discussed but you never know!
Regardless the outcome, any deal will send us sky high!